A phase I study of Nanobodies targeting a G-protein-coupled receptor (GPCR) in the treatment of inflammation

Trial Profile

A phase I study of Nanobodies targeting a G-protein-coupled receptor (GPCR) in the treatment of inflammation

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs Single-domain antibodies (Primary)
  • Indications Inflammation
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2016 According to an Ablynx media release, Novartis received clearance by the FDA to start this phase I study.
    • 09 May 2016 New trial record
    • 29 Apr 2016 According to an Ablynx media release, the company has received clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for this phase I study which is expected to initiate in the second quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top